Tectonic Therapeutic Inc. Common Stock (TECX)

About TECX

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPC…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

60

Website

tectonictx.com/

Fundamentals

1-day range

$34.95$36.76

Market cap

$526.83M

P/E (trailing)

—

P/E (forward)

-7.61

EPS (trailing)

$-4.46

Dividend yield

—

Beta

1.31

Avg. volume

186.3K

Forecasts

9 analyst ratings

Tectonic Therapeutic Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $527.47MP/E —
  $5.97$16.93
• ZURA

  Zura Bio Limited Class A Ordinary Shares

  $5.73

  ▼ 2.05%
  Market cap $524.39MP/E —
  $1.88$7.44
• PRME

  Prime Medicine Inc. Common Stock

  $3.62

  ▼ 0.69%
  Market cap $507.54MP/E —
  $2.67$6.94
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $555.49MP/E —
  $5.37$17.58
• VALN

  Valneva SE American Depositary Shares

  $6.43

  ▼ 2.13%
  Market cap $491.51MP/E —
  $2.03$5.34
• PROK

  ProKidney Corp. Class A Ordinary Shares

  $1.84

  ▲ 1.10%
  Market cap $471.21MP/E —
  $1.3$3.48

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

13.96M

Total value held

$416.45M

Institutional holders

108